Compare ENTA & KTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENTA | KTF |
|---|---|---|
| Founded | 1995 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 378.0M | 361.2M |
| IPO Year | 2012 | N/A |
| Metric | ENTA | KTF |
|---|---|---|
| Price | $13.20 | $8.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $20.40 | N/A |
| AVG Volume (30 Days) | ★ 204.2K | 146.9K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.54% |
| EPS Growth | ★ 29.93 | N/A |
| EPS | N/A | ★ 0.39 |
| Revenue | ★ $102,814,000.00 | N/A |
| Revenue This Year | $7.76 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $22.21 |
| Revenue Growth | ★ 16.48 | N/A |
| 52 Week Low | $7.05 | $8.63 |
| 52 Week High | $17.15 | $9.37 |
| Indicator | ENTA | KTF |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 27.15 |
| Support Level | $12.48 | N/A |
| Resistance Level | $13.98 | $9.26 |
| Average True Range (ATR) | 0.62 | 0.05 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 18.47 | 4.54 |
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.